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Abstract
Background: We conducted in-depth interviews to characterize reasons for COVID-19 vaccine hesitancy in emergency
department (ED) patients and developed messaging platforms that may address their concerns. In this trial, we seek to
determine whether provision of these COVID-19 vaccine messaging platforms in EDs will be associated with greater
COVID-19 vaccine acceptance and uptake in unvaccinated ED patients.
Methods: This is a cluster-randomized controlled trial (RCT) evaluating our COVID-19 vaccine messaging platforms in
seven hospital EDs (mix of academic, community, and safety-net EDs) in four US cities. Within each study site, we
randomized 30 1-week periods to the intervention and 30 1-week periods to the control. Adult patients who have not
received a COVID-19 vaccine are eligible with these exclusions: (1) major trauma, intoxication, altered mental status, or
critical illness; (2) incarceration; (3) psychiatric chief complaint; and (4) suspicion of acute COVID-19 illness. Participants
receive an orally administered Intake survey. During intervention weeks, participants then receive three COVID-19
vaccine messaging platforms (4-min video, one-page informational flyer and a brief, scripted face-to-face message
delivered by an ED physician or nurse); patients enrolled during non-intervention weeks do not receive these
platforms. Approximately, an hour after intake surveys, participants receive a Vaccine Acceptance survey during which
the primary outcome of acceptance of the COVID-19 vaccine in the ED is ascertained. The other primary outcome of
receipt of a COVID-19 vaccine within 32 days is ascertained by electronic health record review and phone follow-up. To
determine whether provision of vaccine messaging platforms is associated with a 7% increase in vaccine acceptance
and uptake, we will need to enroll 1290 patients.
Discussion: Highlighting the difficulties of trial implementation during the COVID-19 pandemic in acute care settings,
our novel trial will lay the groundwork for delivery of public health interventions to vulnerable populations whose only
health care access occurs in EDs.
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Conclusions: Toward addressing vaccine hesitancy in vulnerable populations who seek care in EDs, our cluster-RCT
will determine whether implementation of vaccine messaging platforms is associated with greater COVID-19 vaccine
acceptance and uptake in unvaccinated ED patients.
Trial status: We began enrollment in December 2021 and expect to continue through 2022.
Trial registration: ClinicalTrials.govNCT05142332. Registered 02 December 2021.
Keywords: COVID-19, Vaccine hesitancy, Randomized controlled trial

Background
COVID-19 illness has led to over 915,000 deaths in the
United States (US) as of February 15, 2022 [1]. SARSCoV-2 vaccines are a powerful tool for mitigating the
risk of acute COVID-19 illness and its sequelae during
the COVID-19 pandemic. Efforts to mitigate the risk of
COVID-19 illness by vaccination are predicated on
broad acceptance of vaccines by a substantial majority of
the population to achieve herd immunity [2, 3]. Vaccine
hesitancy (unwillingness to receive a COVID-19 vaccine)
has persisted as a major barrier to reaching this target in
the US, with approximately 15% of national online survey respondents saying that they would not get a
COVID-19 vaccine in the spring of 2021 [4, 5].
The major limitation of most prior investigations of
COVID-19 vaccine hesitancy is that they have been primarily conducted online or by telephone [4–8], a sampling
method that may miss medically underserved and disadvantaged populations and may not reflect the attitudes of
patients during true healthcare encounters [9–11]. The
emergency department (ED) setting has been commonly
described by policymakers as “the safety net of the safety
net” [12]. With approximately 140 million visits in the US
annually, EDs serve as the primary (and often only) health
care access point for up to a fifth of the population that
includes a number of vulnerable groups—immigrants,
persons experiencing homelessness, the impoverished,
and the uninsured, many of whom fall into high-risk
categories for poor outcomes from COVID-19 infection
[13–20]. Minorities, especially African Americans and
Latinos, also receive disproportionately high amounts of
primary healthcare access through EDs [16–20]. Broad,
equitable COVID-19 vaccine delivery to vulnerable populations is a critical public health need that EDs are thus
uniquely positioned to address.
With these principles in mind, we previously conducted
the Rapid Evaluation of COVID-19 Vaccination in Emergency Departments for Underserved Patients (REVVED
UP) study, consisting of surveys of medically underserved
populations during ED visits at 15 geographically representative EDs across the US [21]. We found that patients
whose primary health care access occurs in EDs had
greater vaccine hesitancy and particular health care access
barriers, needs, and perceptions about vaccines that

require specific review beyond traditional (non-ED user)
community engagement techniques.
The premise underlying this research (PROmotion of
COvid-19 VA(X)ccination in the Emergency Department—PROCOVAXED) is that efforts toward equitable
distribution of the COVID-19 vaccine, vaccination-based
herd immunity, and prevention of disease in high-risk,
vulnerable populations must go where these vulnerable
populations go for care—the ED. In the first specific aim
toward the goal of decreasing COVID-19 vaccine hesitancy and increasing vaccine uptake in vulnerable ED populations, we conducted in-depth qualitative interviews of
vaccine hesitant ED patients whose primary health care
access occurs in EDs. Through these interviews, we gained
actionable insight regarding reasons for COVID-19 vaccine hesitancy and other barriers to vaccination, the role
of trusted messengers, and specific messaging to address
hesitancy. We then used these findings to develop
population-specific COVID-19 vaccine (PROCOVAXED)
messaging platforms (videos, informational flyers, and
scripts for face-to-face ED provider messaging) that
may address their specific COVID-19 vaccine concerns.
The objectives of this trial are to determine (1) whether
implementation of PROCOVAXED trusted messaging platforms in EDs is associated with increased COVID-19 vaccine
acceptance (the converse of vaccine hesitancy) in ED patients
at the time of their ED visit and (2) whether implementation
of PROCOVAXED platforms in EDs is associated with increased COVID-19 vaccine uptake in unvaccinated ED patients (30 to 32 days after their index ED visit). Our central
study hypothesis is that implementation of PROCOVAXED
messaging platforms in EDs will be associated with greater
COVID-19 vaccine acceptance and uptake in unvaccinated
ED patients. Herein, we present our trial’s rationale, methodology, and study procedures.

Design
This is a cluster-randomized controlled trial (RCT) of implementation of our multimedia COVID-19 messaging
platforms in seven hospital EDs (mix of academic, community, and safety net EDs) in four US cities: (1) San Francisco, CA: Zuckerberg San Francisco General Hospital
[ZSFGH] and UCSF Medical Center—Parnassus; (2)
Philadelphia: Thomas Jefferson University Hospital,
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Methodist Hospital and Jefferson Torresdale Hospital; (3)
Seattle, WA: Harborview Medical Center; and (4) Durham, NC: Duke University Medical Center.
Rationale for cluster design

Our primary goal with this research is to determine
whether implementation of PROCOVAXED as an ED-site
level intervention results in greater acceptance and uptake
of COVID-19 vaccines in vulnerable ED populations. Each
site sees approximately 125–250 patients per day, and
applying or not applying the intervention (delivery of
PROCOVAXED messaging) under an individual patient
randomization scheme in this high workflow, rapid patient
turnover ED environment is less practical and would likely
result in extensive cross-contamination between intervention and control arms. Therefore, randomization by weeks
at sites and removal of the intervention from the site completely during specified time periods of non-intervention
was considered to be the optimal approach. Although a
single switch of the intervention at each site (i.e., steppedwedge trial design) is easier to enact, changes in general
population attitudes over time limit the validity of this trial
method. We expect changes in baseline acceptance of the
COVID-19 vaccine over time, which would likely introduce substantial bias toward or against the intervention.
These practical and methodological benefits of the week
unit cluster RCT far outweigh the smaller sample size and
easier analysis with an individual patient unit RCT or a
stepped-wedge design.
Randomization plan

Randomizations are computer-based pseudo-random sequences of 7-day (1 week) periods. Within each of the
seven study sites, we randomized 30 1-week periods to
the intervention group and 30 1-week periods to the
control group to ensure equal allocation to control and
intervention settings. We stratified sequences by study
week period so that three centers will be in the control
condition for one week and four centers will be in the
experimental condition for 1 week, or vice versa, in a
Latin square design. This is intended to minimize the effect of secular trends on the comparison of the intervention. We generated a 60-week study calendar based on
this randomization scheme. To maintain masking of allocation, sites are notified of their treatment assignment
for the next week no more than 3 days prior to that
week.
Study enrollment procedures

Practical budget considerations and limits on research
personnel in patient care areas during the COVID-19
pandemic preclude 24/7 study enrollment and delivery
of the study intervention. Thus, we are enrolling a
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convenience sample of patients across all study sites, approaching all potentially eligible adult patients who
present to study EDs during 6 to 10-h weekday blocks,
typically beginning at approximately 09:00 and continuing to approximately 17:00. Sites have leeway to choose
their preferred daytime enrollment block periods, as
long as those blocks remain consistent between study
arms throughout the study. Research staff avoid telling ED providers whether this is an intervention versus
control period.
All sites have ED dashboards that include patient age,
chief complaint, and COVID vaccination status. Research staff review these dashboards, query ED providers
regarding suitability for the study, and approach patients
who potentially meet inclusion/exclusion criteria. We include adult (> 17 years of age) patients presenting to
study sites according to the following inclusion criteria:
(1) not already vaccinated for SARSCOV2; (2) able to
provide informed consent; (3) fluent in English or Spanish (inclusion of Spanish speakers will only occur at
three sites that have Spanish-speaking research staff);
and (4) anticipated ability to complete study intervention
in ED, i.e., ability to watch the short video. We exclude
patients with the following characteristics: (1) inability to
participate in a survey because of major trauma, intoxication, altered mental status, or critical illness; (2) in police custody or incarceration; (3) psychiatric chief
complaint or on psychiatric hold; (4) medical reason (as
per the ED provider or patient) that they cannot receive
a COVID-19 vaccine (e.g., instructed by their primary
physician that they should not receive a COVID-19 vaccine); and (5) suspicion of acute COVID-19 illness with
any of the following constituting suspicion: cough, fever,
myalgias, shortness of breath, sore throat, chest pain,
and patient or provider declaration of suspicion of acute
COVID-19. Of note, given that many patients are receiving COVID-19 testing for surveillance reasons (e.g., routine admission testing), performance of a COVID-19 test
itself is not an automatic exclusion. However, if a
COVID test returns a positive result, the patient is
excluded.
For potential study patients, we deliver scripted verbal
consent for two short study surveys (the Intake Survey
[see Additional File 1] and the Vaccine Acceptance Survey [see Additional File 2 & 3]) in a manner that we
have used with numerous other ED survey studies, including those that have addressed COVID-19 vaccine
hesitancy [21]. Considering that the intervention
(COVID-19 vaccine messaging) is entirely educational
and firmly a part of standard best-practice ED care
(COVID-19 messaging is currently enacted in EDs
across the US), only verbal consent is required. Patients
are informed that they will not be compensated for
participation.
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Survey administration

For patients agreeing to the above surveys and meeting
inclusion/exclusion criteria, the Intake Survey is administered to assess demographics and other study subject
characteristics. All surveys are delivered orally—research
staff read questions to the participants in their preferred
language and record responses.
Approximately 1 h after the Intake Survey, the Vaccine
Acceptance Survey is administered. Although we are
using an hour as our general guide for this Vaccine Acceptance Survey, we expect variability in patients’ visit
time and care plans in the ED (e.g., patients may be
undergoing procedures or away from their rooms for xrays precluding the survey at 1 h). Therefore, research
staff can conduct this survey anytime between 30 min
and 6 h after the Intake survey. The Vaccine Acceptance
Survey for Intervention [see Additional File 2] arm participants also assesses whether the messaging platforms
affected their views on getting a COVID-19 vaccine. The
Vaccine Acceptance Survey for Non-Intervention [see
Additional File 3] arm participants asks whether anyone
delivered messages about COVID-19 vaccines to them
in the ED. The last question in the Vaccine Acceptance
Survey in both arms of the study is “Would you accept
the COVID vaccine in the emergency department today
if your doctor asked you?”
For all subjects saying “No” to the question “Would
you accept the COVID vaccine in the emergency department today if your doctor asked you?”, research staff ask
if they can contact them by phone and review their electronic health records (EHR) in a month for follow-up,
with options to agree to both phone calls and EHR review, only phone call (no EHR review), and only EHR review (no phone call). If the participant agrees to followup, then the CRC obtains the relevant full written informed consent, including separate HIPAA document
agreements. They then ask subjects for their best phone
number(s) to reach them for a follow-up phone call.
They also ask for 1-month follow-up in those subjects
who said “Yes” to accepting the COVID-19 vaccine in
the ED but did not get it in the ED.
Study intervention

The intervention consists of three COVID-19 messaging
platforms that were developed by our team in the first
phase of this work, using findings from qualitative interviews focused on understanding vaccine hesitancy and
on potential methods to addressing this hesitancy.
1) Videos: Short (approximately 4-min) Public Service
Announcement type videos that are presented on
an electronic tablet. We have developed five versions; all with the same wording in the message, but
each with a different pair of physician messengers:
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a. African American physicians
b. Latinx physicians, English version
c. Latinx physicians, Spanish version
d. Mixed race physicians
e. White physicians
2) Printed materials: One-page information flyer. We
have developed five versions; all with the same format and wording/captions in the flyer, but each
with different pictures of patients receiving the vaccine and health care providers administering the
vaccines.
a. Predominantly African American patients and
providers
b. Predominantly Latinx, English version patients
and providers
c. Predominantly Latinx, Spanish version patients
and providers
d. Mixed race patients and providers
e. Predominantly White patients and providers
3) Face-to-face messaging: A short (< 1 min) scripted
message printed on a sheet of paper and delivered
by one of the patient’s providers in the ED
(physician, nurse or mid-level practitioner).
At the end of the Intake Survey, research staff ask patients if they are willing to watch a short video about
COVID-19 vaccines. If they agree to watch the video, research staff show them a video on the electronic tablet.
After finishing with the video (or after refusal to watch
the video), the research staff ask the patient if they
would like to see an informational flyer about COVID19 vaccines. If the patient agrees, then staff hand the patient the flyer. Staff then ask the subject if they may return in approximately an hour for the Vaccine
Acceptance Survey. After leaving the participant’s room,
staff ask one of the patient’s primary providers (doctor,
mid-level practitioner, or nurse) to deliver the COVID19 face-to-face vaccine message, using the scripted message. If delivery of the messaging platforms is interrupted or if the patient is no longer able to receive the
intervention platforms because of change in their status
or clinical care needs, the research staff notes this on
data forms.
We deliver messaging from our platform libraries in
patients’ preferred language (English or Spanish only). In
our previous qualitative interviews, patients reported
preferences for ideal vaccine messengers as being congruent with their race and ethnicity. Thus, research staff
match videos and informational flyers with subjects’ ethnic and racial characteristics declared during the Intake
Survey (e.g., Latinx messenger on video with Latinx subject). All surveys and interventions are delivered in realtime patient visits in site EDs, during waiting times such
that they do not interfere with patient care (Fig. 1).

Rodriguez et al. Trials

(2022) 23:332

Page 5 of 10

Fig. 1 Intervention blocks study flow

Description of usual care

Study procedures during control period (non-intervention) blocks are identical to procedures in intervention blocks with the exception that patients are
not given the intervention (Fig. 2). Randomization to
the control group does not in any way preclude delivery of vaccine messaging by ED providers, and research staff are not telling providers to avoid
delivering vaccine messaging. During control group
weeks, ED providers are free to practice their usual
practice of delivering or not delivering vaccine
messaging.
Provider notification of COVID-19 vaccine acceptance

At this time, all of our EDs have the capability of administering COVID-19 vaccines, and we expect that this
vaccine availability will continue for at least the first 6
months of the trial. The last question in the Vaccine Acceptance Survey in both arms of the study is “Would
you accept the COVID vaccine in the emergency department today if your doctor asked you?” When a participant says they will accept the vaccine, research staff ask
the patient if they can notify the patient’s providers that
they said they will accept the vaccine. They also ask the
participant if research staff can check to see if they receive the vaccine in the ED. Other than this question
and notification, research staff do not push that they get
vaccinated. They do not provide any counseling and do
not tell patients whether they qualify for a COVID-19
vaccine in the ED.
When patients agree to the vaccine and agree that research staff can notify the ED providers of vaccine acceptance, research staff notify the provider of vaccine
acceptance. We are clarifying with providers that we

Fig. 2 Control period blocks study flow

have not reviewed their medical history, indications, and
contraindications to COVID-19 vaccination. Research
staff emphasize with both patient and provider that it is
up to the provider to determine whether the patient can
receive the vaccine in the ED (research staff are merely
informing providers that the patient would accept it if
offered). Staff later check with the provider and patient
to see if the patient received the COVID-19 vaccine in
the ED.
Data entry and management

We manage data using REDCap, hosted by the core site
(UCSF), for secure data entry and management. Research staff have the option of inputting survey responses to the REDCap database on iPads in real time
or using paper surveys (and later inputting into REDCap). For study subjects who have consented to phone
and EHR follow-up, separate files linking patient identifiers (medical record numbers and phone numbers) to
unique study ID numbers are housed at individual study
sites in files, separate from other study data. We developed a detailed data dictionary to ensure consistent
standards across sites and to reduce missing or erroneous data using the REDCap data quality tool.
Primary outcomes and ascertainment

Our primary outcome of acceptance of a COVID-19
vaccine in the ED is ascertained in both arms of the
study by the question in the Vaccine Acceptance Survey,
“Would you accept the COVID vaccine in the emergency department today if your doctor asked you?”:
“Yes” to this question = acceptance; “No” or “Unsure” =
non-acceptance.
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Our primary outcome of COVID-19 vaccine uptake
32 days after their index ED visit is ascertained via (1)
confirmation of receipt of a COVID-19 vaccine during
their index ED visit, (2) review of EHR for receipt of a
COVID-19 vaccine at 28 days, and (3) phone follow-up
at 28 to 32 days—response to the question “Have you received a COVID-19 vaccine since you were in the Emergency Department?” Research staff conducting phone
30-day follow-up are blinded to the participants’ study
arm allocation. We conduct up to three attempts to
reach participants by phone. If we are unable to reach
the participant on the third call, we leave a voice message with our research study number for them to call us
back.
Statistical approach

This is a superiority trial in which we seek to verify our
central study hypothesis that provision of PROCOVAXED will result in greater acceptance and uptake of
the COVID-19 vaccine. Following the recommendations
of Hussey and Hughes [22, 23], our statistical analyses
will focus on comparing the vaccine uptake rates during
intervention periods and control periods using mixed effects logistic models. The outcomes of interest are the
binary indicators of whether a patient will accept the
COVID-19 vaccine (“Will you accept the COVID-19
vaccine if it was offered to you”—yes/no) and whether
they have received a COVID-19 vaccine (uptake—yes/
no) upon follow-up at 30 to 32 days. Models will include
a random center effect to accommodate potential
within-center characteristics (e.g., case mix, demographics), as well as terms for time and intervention. Hypothesis tests will focus on the statistical significance of the
intervention indicator. We will fit the mixed effects
models using maximum likelihood and routines in Stata.
We will test our primary hypothesis and analyze outcomes according to the study arm (index visit in intervention time period vs control time period) to which patients
were allocated, regardless of whether they received PROCOVAXED messaging platforms or not—an intention to
treat analysis. We will also conduct a per-protocol analysis,
in which we assess results that would occur if they actually
did or did not receive PROCOVAXED messaging (e.g.,
viewed the video clip given to them) during their index
visit (ascertained by direct questioning in the Vaccine Acceptance Survey). When compared to the primary analysis, the per-protocol analysis will allow us to dissect the
reasons for success (or failure) in demonstrating improved
vaccine acceptance and uptake with PROCOVAXED. For
example, if we find better acceptance and uptake in the
per protocol analysis and not in the intention to treat allocation analysis, we would subsequently seek ways to improve delivery of PROCOVAXED messaging. Conversely,
if both analyses fail to improve acceptance, then the
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PROCOVAXED intervention truly fails and other efforts
to improve delivery would not be indicated.
In addition to the effects on total ED population vaccine
acceptance, we will also examine the effect of PROCOVAXED on acceptance in patient sub-groups, especially
African Americans, Latinos and patients who lack primary care (as determined by direct questioning). We will
additionally stratify outcomes by study site (representing
different regions of the country and different communities), age, gender, race/ethnicity, as well as patient-level
experience characteristics, such as having had COVID19.
We will also analyze data from Intervention group
Vaccine Acceptance Survey assessing participants’ views
on the vaccine messaging platforms. This data includes
opinions on which platforms were helpful in promoting
vaccine acceptance and feedback on improving the
platforms.
Sample size considerations

The sample size calculations for this research are governed by testing the hypothesis that implementation of a
trusted messenger informational program will be associated with increased acceptance and uptake of COVID-19
vaccines in unvaccinated ED patients. Considering the
commonality of hesitancy (non-acceptance), the high
benefit of increasing acceptance, and the negligible risk
of the intervention (a trusted messaging program), even
a small effect size of increased acceptance would be a
clinically important difference. By investigator consensus
and in consultation with a panel of health policy experts,
we have determined that vaccine messaging platforms
would be clinically useful if they increased acceptance by
7%. Similarly, with the same considerations of negligible
risk, we determined that these platforms would be useful
with an effect size on vaccine uptake of 7%.
Our sample size calculations accommodate the
randomization of clusters design consisting of 1-week
periods (PROCOVAXED platform weeks versus nonintervention weeks) to the intervention at each of seven
sites. To avoid period effects, we will assign sites using a
Latin square design S2. We base the sample size calculation on the comparison of the proportion of patients
who accept the vaccine between the PROCOVAXED
and usual care time periods using standard formulae for
individual randomization. We have verified that these
sample sizes are conservative by simulation of data using
a mixed random effects model.
When our protocol was originally written in February
2021, vaccines were not widely available and the degree
of baseline vaccine acceptance was unknown. We therefore calculated sample sizes for a wide range of vaccine
acceptance and uptake rates with a plan to measure
these in the non-intervention (control) group during the
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first two weeks of the trial. After the first month of the
study, we estimated that our baseline vaccine acceptance
and uptake rates (without intervention) will be approximately 15%. With this baseline uptake rate of 15%, we
find that at an alpha = 0.05 level and a power of at least
0.9, we will need to enroll 1290 patients (645 in each
arm) in the study to detect the difference of interest (a
setting in which the vaccine acceptance rate will increase
by 7% in PROCOVAXED weeks). With this same baseline 15% rate of uptake and the same specifications for
power, we will need to enroll 1290 patients (645 in each
arm) to detect a vaccine uptake difference of 7%. Thus,
our target enrollment for this implementation trial is
1290 subjects across all sites.
In terms of total projected time for enrollment, we expect enrollment of four subjects per site per week at the
seven sites or 28 enrollees per week. We therefore expect to attain our target enrollment of 1290 subjects in
approximately 46 weeks.
Early termination of study monitoring committee (ETSMC)

In our study, we seek to determine whether implementation of COVID-19 vaccine messaging platforms in the
ED result in greater COVID-19 vaccine acceptance and
uptake in unvaccinated ED patients. One of the primary
goals of the data safety and monitoring boards for most
studies is to prevent the ongoing use of unsafe treatments. We do not anticipate serious adverse events, and
this safety goal does not apply to this study for the following reasons: (1) We are not delivering a drug or
other physical intervention in this trial; the intervention
is vaccine messaging. (2) We are not testing or measuring the safety of any drug or therapy—COVID-19 vaccines have undergone rigorous testing in multiple other
studies; (3) The intervention (vaccine messaging) is an
accepted and highly recommended public health intervention in all patient care settings; (4) Randomization to
non-intervention week does not preclude delivery of vaccine messaging by providers. Providers are unaware of
treatment arms during the study, and we are not telling
providers to avoid delivering vaccine messaging. During
non-intervention weeks, providers are free to practice
their usual practice of delivering or not delivering vaccine messaging; (5) We are not telling patients that they
qualify for the COVID-19 vaccine in the ED. We are
only asking this question: “Would you accept the
COVID vaccine in the emergency department today if
your doctor asked you?”; and (6) We are not prescribing
or ordering vaccines in study patients. We are merely
informing ED providers that their patient would accept
the vaccine if they were offered it in the ED. We are emphasizing with providers that we have not reviewed their
medical history, indications and contraindications to
COVID vaccination. The decision as to whether they
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would offer or give the vaccine is entirely left up to the
ED provider.
Given the above-described rationale about safety, there
remain two primary considerations with regard to stopping the trial before sample size enrollment in this study:
(1) Decreased vaccine acceptance or decreased vaccine
uptake in the intervention arm—it is possible that the
intervention may increase vaccine hesitancy (decrease
vaccine acceptance and uptake) and that this ineffectiveness could be determined statistically before full patient
enrollment. Under this circumstance, continuation of
the trial would therefore be futile and not ethically
justified.
(2) Superior efficacy of the intervention—conversely, it
is also possible that the intervention may clearly improve
vaccine acceptance and uptake before full sample size
enrollment. In this case, continuation of the study in the
non-intervention arm would no longer be justified.
To assess for either of the two early termination scenarios, we have established a three-person ETSMC to
conduct a blinded interim analysis at the one-quarter,
one half, and three-quarter points of study enrollment
(after enrollment of 323, 645, and 977 patients). We will
provide the ETSMC a detailed algorithm with clearly
identified criteria for this early termination assessment.
Steering committee, operations, and manual of operating
procedures

We assembled a Steering Committee consisting of the PI
and Site PIs, who meet monthly to discuss implementation and the overall direction of the study. We developed
orientation materials to familiarize the ED Sites with the
study protocol. Each site employs one or more RCs, who
report to the site principal investigator (PI) and are responsible for day-to-day study implementation. We developed and disseminated a manual of operating
procedures (MOP) with standard personnel training
methods, including education kits with scripts, summary
cards, and PowerPoint presentations to assist coordinators in the orientation of site clinicians and other staff to
our study protocol. We convened videoconference calls
to review this summary and develop plans for
optimization of study procedures to improve usability
and workflow. We continue to update the MOP to reflect changes in study procedures.
We reviewed study implementation procedures with
sites individually and at group conferences prior to
study initiation. We conducted walk-through sessions
of workflow on hypothetical study subjects in both
intervention and non-intervention study arms. We
continue to refine procedures with updates delivered
to site PIs and research staff during weekly videoconferences. We maintain a study hotline during primary
study hours and encourage study personnel to contact
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the PI and Central Study Coordinator for all issues
and queries.
We implement rigorous methods for clinical trial quality assurance and performance improvement, including
(1) systematic review of enrollment logs, (2) quarterly
audits of random samples of data for accuracy and missing elements, and (3) structured review of protocol deviations or violations. The Central Study Coordinator
prepares monthly summary report cards, tabulating individual site quality assurance metrics for review during
scheduled Steering Committee calls. The study PI discusses site-specific data with site PIs individually and
summarizes these data collectively during Steering Committee calls, with prompt dissemination of plans for
process improvement.
We submit protocol modifications to the central IRB
for review. After approval, we notify all relying sites and
discuss implementation of these changes at weekly meetings. We notify the study sponsor of modifications and
revise our Clinicaltrials.gov protocol accordingly.
Dissemination

Beyond Clinicaltrials.gov, the investigators are committed
to broad, open access dissemination of our findings. We
plan to present abstracts at national symposia and submit
manuscripts describing our findings to open access journals. We will deposit other relevant study tools in the
PhenXToolkit (https://tools.niehs.nih.gov/dr2/index.cfm/
resource/24262). We will also share data upon appropriate
request through UCSF Datashare mechanisms.

Discussion
Emergency departments provide both acute care and
vital public health services to large swaths of the US
population, especially disadvantaged populations who
lack primary care. In our previous research, we identified a critical need to address COVID-19 vaccine
hesitancy and uptake in vulnerable populations who
primarily seek care in the ED. In this trial, we seek to
address the critical need for COVID-19 vaccine messaging and access, testing the hypothesis that implementation of COVID-19 messaging platforms in EDs
will improve vaccine acceptance and uptake in unvaccinated ED patients.
Expected key results

In addition to determining whether implementation of
COVID-19 messaging platforms in EDs improves vaccine acceptance and uptake in the general population of
unvaccinated ED patients, we will assess the efficacy of
messaging platforms in a number of other subpopulations. Given that PROCOVAXED messaging may work
for some patient sub-groups and not others, these additional analyses will guide targeted messaging. Data on
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participants’ views regarding the three different messaging platforms will guide future modifications of vaccine
messaging.
Strengths and limitations

Our research is particularly innovative in a number of
ways, and may set a new paradigm for public health interventions to vulnerable populations, including messaging for other vaccinations like influenza, through the
ED. The sheer number of ED visits across the country
affords our research very high impact. If our intervention
increases vaccine acceptance and uptake in 7% of vaccine hesitant patients, this could potentially lead to the
delivery of tens of thousands of COVID-19 vaccines to
people who would not otherwise get vaccinated.
Perhaps our greatest limitation in this research is the
limited pool of unvaccinated patients over time in our
EDs. When we began this work in December 2020 to
March 2021, vaccine hesitancy was expressed by over 40%
of the populations in our EDs. As of January 2022, national and local efforts have led to very high rates of vaccine uptake in our cities, ranging from 85 to 94%. While
emphasizing that high vaccination rate is a great thing, we
now have a limited pool of unvaccinated patients in our
EDs, who may be particularly steadfast in their views and
resistance to COVID-19 vaccine messaging.
Our work highlights the difficulties of performing an
RTC during a pandemic in the acute care setting where
most acutely ill COVID-19 patients receive care—the
ED. Surges in the pandemic, particularly with the Omicron variant, may make enrollment difficult. At our
study sites, as many as a third of all patients in the ED
during January 2022 were either under suspicion for
COVID-19 or tested positive for COVID-19 in the
absence of symptoms; these patients therefore were excluded from consideration for the study. Additionally,
the surge has led to substantial ED boarding of admitted
patients, in turn leading to major decreases in patient
turnover in the ED. These factors may lead to much
slower enrollment and longer time to reach our sample
size than originally anticipated.
Research staffing to conduct the in-person study procedures in the ED also presents significant challenges.
While all research staff have received COVID-19 vaccines and boosters, research team safety and avoiding
undue exposure are top priorities. With high levels of
acute COVID-19 infections and need for quarantine protocols among clinical and research staff at our institutions during surges, we expect that there will be days in
which we will not be able to conduct the study.

Trial status
All study procedures were approved by the UCSF Committee on Human Research as a central institutional
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review board (protocol #21-34004; initial approval 4/27/
21, final revision approved 12/2/21), with multi-site reliance mechanisms in place at the non-UCSF sites. We
have registered our trial in the Clinicaltrials.gov
depository (h t tp s: / / c lin ic a ltr ia ls. g o v/ c t2/show/
NCT05142332). We began enrollment on December 6,
2021. Unless early termination criteria are met, we expect to continue enrollment through December 2022.

Conclusions
We have identified a critical need for messaging to address COVID-19 vaccine hesitancy in ED patients. At
seven safety net emergency departments, the PROCOVAXED cluster-RCT will test the hypothesis that Implementation of PROCOVAXED messaging platforms in
EDs will be associated with greater COVID-19 vaccine
acceptance and uptake in unvaccinated ED patients.
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